FDA Novel Drug Approvals 2023: 30 New Life-Saving Treatments You Need to Know

Описание: In 2023, the FDA approved several novel drugs that are making significant breakthroughs in medicine. In this video, we cover 30 important new therapies, their indications, and how they are transforming patient care. From cancer treatments to rare disease therapies, each approval is bringing hope to patients around the world. Here's a look at these groundbreaking drugs:

Wainua (eplontersen) - For polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Filsuvez (birch triterpenes) - For wounds associated with epidermolysis bullosa.
Fabhalta (iptacopan) - For paroxysmal nocturnal hemoglobinuria (PNH).
Ogsiveo (nirogacestat) - For desmoid tumors in adults.
Truqap (capivasertib) - For breast cancer that meets certain criteria.
Ryzneuta (efbemalenograstim alfa-vuxw) - For neutropenia.
Augtyro (repotrectinib) - For ROS1-positive non-small cell lung cancer.
Defencath (taurolidine, heparin) - For reducing catheter-related bloodstream infections in hemodialysis patients.
Fruzaqla (fruquintinib) - For refractory metastatic colorectal cancer.
Loqtorzi (toripalimab-tpzi) - For recurrent or metastatic nasopharyngeal carcinoma.
Omvoh (mirikizumab) - For ulcerative colitis.
Agamree (vamorolone) - For Duchenne muscular dystrophy.
Bimzelx (bimekizumab) - For moderate to severe plaque psoriasis.
Zilbrysq (zilucoplan) - For generalized myasthenia gravis.
Velsipity (etrasimod) - For moderately to severely active ulcerative colitis.
Rivfloza (nedosiran) - For lowering urinary oxalate levels in primary hyperoxaluria type 1.
Pombiliti (cipaglucosidase alfa) - For late-onset Pompe disease.
Exxua (gepirone) - For major depressive disorder.
Ojjaara (momelotinib) - For myelofibrosis in adults with anemia.
Aphexda (motixafortide) - For multiple myeloma.
Veopoz (pozelimab-bbfg) - For CHAPLE disease (CD55-deficient protein-losing enteropathy).
Sohonos (palovarotene) - For fibrodysplasia ossificans progressiva (FOP).
Elrexfio (elranatamab) - For relapsed or refractory multiple myeloma.
Talvey (talquetamab) - For relapsed or refractory multiple myeloma.
Izervay (avacincaptad pegol) - For geographic atrophy secondary to age-related macular degeneration.
Zurzuvae (zuranolone) - For postpartum depression.
Xdemvy (lotilaner) - For Demodex blepharitis.
Vanflyta (quizartinib) - For acute myeloid leukemia.
Beyfortus (nirsevimab-alip) - For preventing RSV in infants.
Ngenla (somatrogon-ghla) - For growth failure due to inadequate secretion of growth hormone.
Learn more about how these drugs are revolutionizing treatments across various medical conditions. Don’t forget to like, subscribe, and hit the notification bell for more updates on breakthrough drug approvals! #FDAApprovals #NewDrugApprovals #MedicalBreakthrough

Warning: The information provided in this video is for educational and informational purposes only and is not intended as medical advice. It is not a substitute for professional medical diagnosis, treatment, or advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have learned from this video or any linked materials.